Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Dimerix Limited

INVESTOR PRESENTATION - Dimerix Limited

ASX:DXB

Dimerix Limited

Health

Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.

Read more

Market Cap

$45.51m

Price at Close

$0.23

4w avg. Volume

752.43k

4w avg. Turnover

$162.76k

Announcements
announcementt+2 movementdate
  • Investor Presentation

    Periodic Reports

  • -12.77%

    15 Dec 2020

-12.77%

15 Dec 2020
  • Second Study to Include DMX-200 in COVID-19 Patients

    Progress Report · Market sensitive

  • +3.92%

    29 Nov 2020

+3.92%

29 Nov 2020
  • Notification of Expired Options

    Issued Capital

  • -1.89%

    15 Nov 2020

-1.89%

15 Nov 2020
  • ARDS in COVID-19 Patients Protocol Published

    Progress Report · Market sensitive

  • -7.14%

    08 Nov 2020

-7.14%

08 Nov 2020
  • Secondary Trading Notice Pursuant to Section 708A(5)(e)

    Issued Capital

  • -8.93%

    27 Oct 2020

-8.93%

27 Oct 2020
  • Appendix 2A

    Issued Capital

  • -8.93%

    27 Oct 2020

-8.93%

27 Oct 2020
  • Positive Additional Data to Support DMX-200 Development

    Periodic Reports · Market sensitive

  • -1.85%

    26 Oct 2020

-1.85%

26 Oct 2020
  • Quarterly Appendix 4C and Activities Report

    Commitments test entity quarterly reports · Market sensitive

  • -3.57%

    22 Oct 2020

-3.57%

22 Oct 2020
  • Receipt of R&D Tax Incentive

    Progress Report · Market sensitive

  • -1.75%

    20 Oct 2020

-1.75%

20 Oct 2020
  • Shareholder Update

    Progress Report

  • -5.08%

    19 Oct 2020

-5.08%

19 Oct 2020
Market Data

Current Price

$0.23

52WK HIGH

$0.78

52WK LOW

$0.105

1YR RETURN

+64.29%

1YR RETURN VS. SECTOR

+25.79%

90 DAY RETURN

-14.81%

ASX RANK

1,190

/2,046

SECTOR RANK

108

/168

SHARES OUTSTANDING

197.87m
ASX:DXB

Dimerix Limited

Health

Dimerix is a clinical stage drug development company. The Company’s lead drug candidate DMX-200 is a chemokine receptor blocker. The Company’s clinical plan involves combining DMX-200 with Irbesartan, a angiotensin receptor blocker indicated for the treatment of hypertension and nephropathy in patients with kidney disease. DMX-200 is currently being tested in two Phase II clinical trials. Both trials are fully recruited and are due to report results in Q2 2020. The first study is targetting the rare chronic kidney disease FSGS and the second is targetting diabetic kidney disease. DMX-200 was discovered using the Company’s proprietary Receptor-HIT assay. Recently the Company announced that it had discovered its next pipeline candidate using the assay, DMX-700. DMX-700 will be investigated for the use in treating Chronic Obstructive Pulmonary Disease.

Read more

Market Cap

$45.51m

Price at Close

$0.23

4w avg. Volume

752.43k

4w avg. Turnover

$162.76k

ASX:DXB is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.